Cargando…
The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma
BACKGROUND: The use of chemotherapy regimens with moderate or high risk of febrile neutropenia (defined as having a FN incidence of 10% or more) and the respective incidence and clinical management of FN in breast cancer and NHL has not been studied in Belgium. The existence of a medical need for G-...
Autores principales: | Gerlier, Laetitia, Lamotte, Mark, Awada, Ahmad, Bosly, André, Bries, Greet, Cocquyt, Véronique, Focan, Christian, Henry, Stéphanie, Lalami, Yassine, Machiels, Jean-Pascal, Mebis, Jeroen, Straetmans, Nicole, Verhoeven, Didier, Somers, Luc |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3006392/ https://www.ncbi.nlm.nih.gov/pubmed/21092320 http://dx.doi.org/10.1186/1471-2407-10-642 |
Ejemplares similares
-
Prescribing Empiric Antibiotics for Febrile Neutropenia: Compliance with Institutional Febrile Neutropenia Guidelines
por: Naeem, Doaa, et al.
Publicado: (2018) -
Developments in the management of febrile neutropenia
por: Pascoe, J
Publicado: (2011) -
Febrile neutropenia with bacterial paronychia
por: Hosono, Yuki, et al.
Publicado: (2018) -
Febrile Neutropenia in Transplant Recipients
por: Nesher, Lior, et al.
Publicado: (2018) -
Febrile Neutropenia in Children with Cancer
por: Paulus, Stéphane, et al.
Publicado: (2008)